176 related articles for article (PubMed ID: 33749549)
21. Identification of quinoline-chalcones and heterocyclic chalcone-appended quinolines as broad-spectrum pharmacological agents.
Atukuri D; S V; R S; L V; R P; M M R
Bioorg Chem; 2020 Dec; 105():104419. PubMed ID: 33142228
[TBL] [Abstract][Full Text] [Related]
22. Unambiguous Identification of β-Tubulin as the Direct Cellular Target Responsible for the Cytotoxicity of Chalcone by Photoaffinity Labeling.
Zhou B; Yu X; Zhuang C; Villalta P; Lin Y; Lu J; Xing C
ChemMedChem; 2016 Jul; 11(13):1436-45. PubMed ID: 27203512
[TBL] [Abstract][Full Text] [Related]
23. Anticancer Potential of Naringenin, Biosynthesis, Molecular Target, and Structural Perspectives.
Prakash O; Singh R; Singh N; Usmani S; Arif M; Kumar R; Ved A
Mini Rev Med Chem; 2022; 22(5):758-769. PubMed ID: 34517796
[TBL] [Abstract][Full Text] [Related]
24. Chalcones: Synthetic Chemistry Follows Where Nature Leads.
Jasim HA; Nahar L; Jasim MA; Moore SA; Ritchie KJ; Sarker SD
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439870
[TBL] [Abstract][Full Text] [Related]
25. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
[TBL] [Abstract][Full Text] [Related]
26. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
27. Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
Yan J; Xu Y; Jin X; Zhang Q; Ouyang F; Han L; Zhan M; Li X; Liang B; Huang X
Eur J Med Chem; 2022 Jan; 227():113897. PubMed ID: 34649064
[TBL] [Abstract][Full Text] [Related]
28. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFα-induced nuclear factor-κB activation inhibition.
Zuo Y; Yu Y; Wang S; Shao W; Zhou B; Lin L; Luo Z; Huang R; Du J; Bu X
Eur J Med Chem; 2012 Apr; 50():393-404. PubMed ID: 22386368
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones.
Yamali C; Gul HI; Ozgun DO; Sakagam H; Umemura N; Kazaz C; Gul M
Anticancer Agents Med Chem; 2017; 17(10):1426-1433. PubMed ID: 28356013
[TBL] [Abstract][Full Text] [Related]
31. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.
Han Y; Riwanto M; Go ML; Ee PL
Eur J Pharm Sci; 2008 Sep; 35(1-2):30-41. PubMed ID: 18598762
[TBL] [Abstract][Full Text] [Related]
32. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
33. A Comprehensive Review of Aminochalcones.
Irfan R; Mousavi S; Alazmi M; Saleem RSZ
Molecules; 2020 Nov; 25(22):. PubMed ID: 33213087
[TBL] [Abstract][Full Text] [Related]
34. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
Xiao J; Gao M; Diao Q; Gao F
Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA
Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968
[TBL] [Abstract][Full Text] [Related]
36. New Hybrid Scaffolds Based on Carbazole-Chalcones as Potent Anticancer Agents.
Rashid F; Zaib S; Ibrar A; Ejaz SA; Saeed A; Iqbal J; Khan I
Anticancer Agents Med Chem; 2021; 21(9):1082-1091. PubMed ID: 32698741
[TBL] [Abstract][Full Text] [Related]
37. Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
Mateeva N; Eyunni SVK; Redda KK; Ononuju U; Hansberry TD; Aikens C; Nag A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2350-2356. PubMed ID: 28442256
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors and promoters of tubulin polymerization: synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents.
Dyrager C; Wickström M; Fridén-Saxin M; Friberg A; Dahlén K; Wallén EA; Gullbo J; Grøtli M; Luthman K
Bioorg Med Chem; 2011 Apr; 19(8):2659-65. PubMed ID: 21459004
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, reactions and application of chalcones: a systematic review.
Shalaby MA; Rizk SA; Fahim AM
Org Biomol Chem; 2023 Jul; 21(26):5317-5346. PubMed ID: 37338020
[TBL] [Abstract][Full Text] [Related]
40. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
